HIV

News

More than 3m people worldwide could be infected with HIV by the end of the decade following a steep fall in international aid funding, says UNAIDS.

News

Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.

News

The FDA is due to deliver a verdict in February on Gilead's once-weekly pill for HIV PrEP, which could expand the options available to patients.

News

Pfizer will relinquish its stake in HIV firm ViiV in a deal valued at $2.1bn that ramps up Shionogi's interest and simplifies its share structure.

News

ViiV's campaign wants communication between women and healthcare workers about HIV to move beyond harmful stereotypes and 'risk' labels.

News

ViiV's injectable HIV PrEP Apretude will soon be an alternative for people in England and Wales who cannot use daily oral options.